These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18760745)

  • 1. [PDE5 inhibitors and satisfaction of patients with erectile dysfunction].
    Cour F
    Prog Urol; 2008 Sep; 18(8):542. PubMed ID: 18760745
    [No Abstract]   [Full Text] [Related]  

  • 2. PDE5 inhibitors: is there more to come besides erectile dysfunction?
    Stief C
    Eur Urol; 2007 Oct; 52(4):943-4. PubMed ID: 17683851
    [No Abstract]   [Full Text] [Related]  

  • 3. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
    Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tadalafil (Cialis) once a day for erectile dysfunction.
    Med Lett Drugs Ther; 2008 Apr; 50(1283):27-8. PubMed ID: 18391900
    [No Abstract]   [Full Text] [Related]  

  • 5. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
    Fusco F; Razzoli E; Imbimbo C; Rossi A; Verze P; Mirone V
    BJU Int; 2010 Jun; 105(12):1634-9. PubMed ID: 20553468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
    Francis SH; Morris GZ; Corbin JD
    Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 11. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erectile dysfunction].
    Stadler TC
    MMW Fortschr Med; 2009 Nov; 151(48):37. PubMed ID: 20085060
    [No Abstract]   [Full Text] [Related]  

  • 13. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.
    Bella AJ; Deyoung LX; Al-Numi M; Brock GB
    Eur Urol; 2007 Oct; 52(4):990-1005. PubMed ID: 17646047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
    Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
    Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.
    Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J
    Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological therapy for the treatment of sexual dysfunction--are we there yet?
    Costabile RA
    J Urol; 2008 Mar; 179(3):819-20. PubMed ID: 18221964
    [No Abstract]   [Full Text] [Related]  

  • 18. Phosphodiesterase type 5 inhibitors: state of the therapeutic class.
    Carson CC
    Urol Clin North Am; 2007 Nov; 34(4):507-15, vi. PubMed ID: 17983891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
    Thurtell MJ; Tomsak RL
    Int J Impot Res; 2008; 20(6):537-43. PubMed ID: 18528398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phosphodiesterase 5 inhibition in erectile dysfunction. Long-term administration without therapeutic advantage].
    MMW Fortschr Med; 2009 Jan; 151(1-2):50-1. PubMed ID: 19227645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.